Yosprala Launched for Secondary Prevention of CV Events in Ulcer-Risk Patients
Aralez announced the availability of Yosprala (aspirin and omeprazole) tablets indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events, and who are at risk of developing aspirin-associated gastric ulcers.
Yosprala combines aspirin, an antiplatelet, and omeprazole, a proton pump inhibitor (PPI)—the only fixed-dose combination currently available. It utilizes the proprietary Intelli-COAT system, which is designed to sequentially deliver immediate-release omeprazole then a delayed-release, enteric-coated aspirin core.
The aspirin component works to reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli; reducing combined risk of death and myocardial infarction (MI) in patients with a previous MI or unstable angina pectoris; and reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris. It is also used in patients who have had revascularization procedures (eg, CABG or PTCA) when there is a pre-existing condition for which aspirin is already indicated.
The omeprazole component reduces the risk of developing aspirin-associated gastric ulcer in patients at risk due to age (≥55 years) or documented history of gastric ulcers.
Yosprala is available as 81mg/40mg and 325mg/40mg strength tablets in 30- and 90-count bottles.
For more information call (866) 207-6592 or visit Yosprala.com.